Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

Fujimura, Taku; Kambayashi, Yahiko; Sato, Yota; Tanita, Kayo; Furudate, Sadanori; Tsukada, Akira; Tono, Hisayuki; Hashimoto, Akira; Aiba, Setsuya

doi:10.1159/000485612

Cited by 10 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the efficacy of ipilimumab in nivolumab-resistant advanced melanoma is only 3.6% [ 3 ], suggesting that additional supportive therapy for anti-PD-1 antibody is needed for nivolumab-resistant advanced melanoma. Indeed, although several supportive therapies to enhance the antitumor immune response of anti-PD-1 antibodies have already been reported [ 3 , 4 , 5 , 6 , 7 , 8 ], unexpected immune-related adverse events were detected at the same time [ 8 ]. In this report, we describe a patient with advanced melanoma treated with nivolumab followed by intensity-modulated radiotherapy (IMRT), which might have triggered bullous pemphigoid (BP).…”

Section: Introductionmentioning

confidence: 99%

Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab

et al. 2018

Self Cite

View full text Add to dashboard Cite

Since the efficacy of ipilimumab on nivolumab-resistant advanced melanoma is extremely low, additional supportive therapy for anti-PD-1 antibody therapy-resistant advanced melanoma is needed. Although several supportive therapies that enhance the antitumor immune response of anti-PD-1 antibodies have already been reported, unexpected immune-related adverse events were detected at the same time. In this report, we describe a patient with advanced melanoma treated with nivolumab followed by intensity-modulated radiotherapy, which might have triggered bullous pemphigoid (BP). Although several cases of BP developing in anti-PD-1 antibody-treated patients have already been reported, in this report, we shed light on the possible pathogenesis of BP developing in a patient treated with nivolumab through M2 macrophages.

show abstract

Section: Introductionmentioning

confidence: 99%

Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…In selected patients, imiquimod combined with other treatments has been shown to be effective in the local control of skin metastases from melanoma [ 168 ] and breast cancer [ 169 , 170 ]. Finally, some reports show a benefit of imiquimod-plus-ICIs combinations in advanced melanomas [ 171 , 172 ].…”

Section: Discussionmentioning

confidence: 99%

Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review

Borella

Preti

Bertero

et al. 2020

IJMS

View full text Add to dashboard Cite

Vulvar cancer (VC) is a rare neoplasm, usually arising in postmenopausal women, although human papilloma virus (HPV)-associated VC usually develop in younger women. Incidences of VCs are rising in many countries. Surgery is the cornerstone of early-stage VC management, whereas therapies for advanced VC are multimodal and not standardized, combining chemotherapy and radiotherapy to avoid exenterative surgery. Randomized controlled trials (RCTs) are scarce due to the rarity of the disease and prognosis has not improved. Hence, new therapies are needed to improve the outcomes of these patients. In recent years, improved knowledge regarding the crosstalk between neoplastic and tumor cells has allowed researchers to develop a novel therapeutic approach exploiting these molecular interactions. Both the innate and adaptive immune systems play a key role in anti-tumor immunesurveillance. Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in multiple tumor types, improving survival rates and disease outcomes. In some gynecologic cancers (e.g., cervical cancer), many studies are showing promising results and a growing interest is emerging about the potential use of ICIs in VC. The aim of this manuscript is to summarize the latest developments in the field of VC immunoncology, to present the role of state-of-the-art ICIs in VC management and to discuss new potential immunotherapeutic approaches.

show abstract

“…96 Moreover, it was described that several cases of melanoma patients successfully treated with combination of ipilimumab and Imiquimod. 97,98 The TLR7/8 agonist Resiquimod (R848) was revealed to activate pDCs and cDCs in vivo, which enhanced T cells priming in regional lymph nodes. And combining PD-L1 antibody treatment with resiquimod is useful to reduce tumor growth in two PD-L1 blockade-resistant tumor models.…”

Section: The Combination Of Nuclei Acid-sensing Immunity With Icis Asmentioning

confidence: 99%

Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies

Chen

et al. 2020

Sig Transduct Target Ther

View full text Add to dashboard Cite

Cancer immunotherapy especially immune checkpoint inhibition has achieved unprecedented successes in cancer treatment. However, there are many patients who failed to benefit from these therapies, highlighting the need for new combinations to increase the clinical efficacy of immune checkpoint inhibitors. In this review, we summarized the latest discoveries on the combination of nucleic acid-sensing immunity and immune checkpoint inhibitors in cancer immunotherapy. Given the critical role of nuclear acid-mediated immunity in maintaining the activation of T cell function, it seems that harnessing the nuclear acid-mediated immunity opens up new strategies to enhance the effect of immune checkpoint inhibitors for tumor control.

show abstract

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod

Cited by 10 publications

References 12 publications

Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab

Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab

Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review

Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies

Contact Info

Product

Resources

About